Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Researchers identify key factors for successful donor lymphocyte infusion in AML patients

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.

24 Jan 2025

Drug in breast cancer trials shows potential for treating blood cancers

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

16 Jan 2025

New approach in fighting leukemia with double-modified natural killer cells

Various forms of blood cancer exist – all of which are grouped together under the term leukemia. One common form of leukemia is acute myeloid leukemia (AML), characterized by a degradation of early blood cell precursors, i.e. stem cells and the precursor cells that develop from them.

18 Dec 2024

Huntsman Cancer Institute joins innovative clinical trials program for blood cancers

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials program designed to match patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with a clinical trial specifically designed for the genetic signature of their disease.

17 Dec 2024

WashU Medicine receives $10.8 million grant to advance blood cancer research

Continuing its role as a leader in leukemia research, Washington University School of Medicine in St. Louis has been awarded a five-year, $10.8 million grant to further its exceptional programs in leukemia and other blood cancers.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

Mapping blood system changes offers new hope for leukemia treatments

Researchers at University of California San Diego School of Medicine and their colleagues have developed the first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime.

6 Dec 2024

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition.

30 Oct 2024

Researchers uncover the link between EVs and tissue damage

A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.

29 Oct 2024

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

23 Oct 2024

NIH launches precision medicine trial to test new treatments for myeloid cancers

The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

23 Oct 2024

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

23 Oct 2024

Case Western Reserve University receives grant to investigate AML treatment for veterans

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve University are investigating a new approach to treat Acute Myeloid Leukemia (AML) in military Veterans.

15 Oct 2024

Evaluating allogeneic transplant for TP53 mutated acute myeloid leukemia

A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Transplant or no transplant for TP53 mutated AML."

12 Oct 2024

Gene therapy offers hope for children with cerebral adrenoleukodystrophy

Cerebral adrenoleukodystrophy (CALD) is a rare progressive, genetic brain disease that primarily presents in young boys, causing loss of neurological function and ultimately leading to early death.

9 Oct 2024

Future directions and challenges in harnessing NK cells against Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles

1 Oct 2024

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

17 Sep 2024

Study shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatments

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other standard-of-care therapies, according to a systematic review and meta-analysis.

11 Sep 2024

Acute Myeloid Leukemia News and Research

Further Reading

Researchers identify key factors for successful donor lymphocyte infusion in AML patients

Drug in breast cancer trials shows potential for treating blood cancers

New approach in fighting leukemia with double-modified natural killer cells

Huntsman Cancer Institute joins innovative clinical trials program for blood cancers

WashU Medicine receives $10.8 million grant to advance blood cancer research

A new era of targeted therapy with antibody–drug conjugates

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Mapping blood system changes offers new hope for leukemia treatments

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Researchers uncover the link between EVs and tissue damage

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

NIH launches precision medicine trial to test new treatments for myeloid cancers

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Case Western Reserve University receives grant to investigate AML treatment for veterans

Evaluating allogeneic transplant for TP53 mutated acute myeloid leukemia

Gene therapy offers hope for children with cerebral adrenoleukodystrophy

Future directions and challenges in harnessing NK cells against Acute Myeloid Leukemia

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

Study shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatments

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News